title: Antitumor effects of snake venom chemically modified Lys49 phospholipase A2-like BthTX-I and a synthetic peptide derived from its C-terminal region.
abstract: The present work evaluates both in vitro and in vivo antitumor activity of BPB-modified BthTX-I and its cationic synthetic peptide derived from the 115-129 C-terminal region. BPB-BthTX-I presented cytotoxicity of 10-40% on different tumor cell lines, which were also susceptible to the lytic action of the synthetic peptide. Injection of the modified protein or the peptide in mice, 5 days after transplantation of S180 tumor cells, reduced 30 and 36% of the tumor size on day 14th and 76 and 79% on day 60th, respectively, when compared to the untreated control group. Thus, these antitumor properties might be of interest in the development of therapeutic strategies against cancer.
authors.affiliation: Instituto de Genética e Bioquímica, Universidade Federal de Uberlândia, Uberlândia, MG, Brazil.
authors.forename: Luiz Carlos
authors.initials: LC
authors.lastname: Gebrim
authors.forename: Silvana
authors.initials: S
authors.lastname: Marcussi
authors.forename: Danilo L
authors.initials: DL
authors.lastname: Menaldo
authors.forename: Carla S R
authors.initials: CS
authors.lastname: de Menezes
authors.forename: Auro
authors.initials: A
authors.lastname: Nomizo
authors.forename: Amélia
authors.initials: A
authors.lastname: Hamaguchi
authors.forename: Elisângela P
authors.initials: EP
authors.lastname: Silveira-Lacerda
authors.forename: Maria Inês
authors.initials: MI
authors.lastname: Homsi-Brandeburgo
authors.forename: Suely V
authors.initials: SV
authors.lastname: Sampaio
authors.forename: Andreimar M
authors.initials: AM
authors.lastname: Soares
authors.forename: Veridiana M
authors.initials: VM
authors.lastname: Rodrigues
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D003435:Crotalid Venoms / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D006801:Humans; D019169:Jurkat Cells; D008239:Lysine / Q000737:chemistry; D008297:Male; D008546:Melanoma, Experimental / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D054467:Phospholipases A2 / Q000737:chemistry; D015202:Protein Engineering; D017434:Protein Structure, Tertiary / Q000502:physiology; D012910:Snake Venoms / Q000737:chemistry / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D003435:Crotalid Venoms; D010446:Peptide Fragments; D012910:Snake Venoms; C078097:bothropstoxin; D054467:Phospholipases A2; D008239:Lysine